Actavis

U.S. stocks were mostly higher on Thursday as both the S&P 500 index and Nasdaq index recorded a fourth straight winning session in a relatively slow news day that was heavy on earnings. The Dow Jones rose as much as 35 points and falling as much as 56 as earnings from Dow listed companies...

U.S. stocks held on to strong gains as U.S. industrial production rose more than projected. The Fed confirmed it will maintain a "friendly" policy that will support the economic recovery. According to Fed Chief Janet Yellen there are three main concerns the central bank is facing. Specifically...

U.S. stocks rose sharply after minutes from the Federal Reserve eased concerns over when the central bank would raise interest rates. The decision to let go of the 6.5 percent unemployment rate threshold for raising interest rates was finalized in early March. Additionally, the Fed's minutes...

U.S. stocks fell as worries piled up over China's economy and further tension in Ukraine. China's combined industrial output growth slowed to 8.6 percent on year in January and February, below a forecast for a 9.5 percent rise and a previous reading of 9.7 percent. The New York Times reported...

Google (NASDAQ: GOOG) is on a bit of an acquisition spree, but it is far from the only company that is buying up startups and stalwarts this year. As most Benzinga readers are aware, Comcast and Time Warner Cable recently announced a massive merger. Actavis and Forest Laboratories announced a...

After a triple-digit intraday high, major indices retreated slightly but still ended the day with impressive gains. The Dow gained about 92 points to close at 16,133.23. The S&P was up 0.6 percent, or about 11 points to close at 1,839.78, and the NASDAQ was up 0.7 percent to 4,267.55....

U.S. stocks overcame mixed economic data and earning reports as the S&P 500 inches towards new all time highs and the Dow recorded an almost triple digit point gain. Jobless claims declined less than expected while consumer prices met expectations and rose slightly. Data from the...

U.S. stocks finished the day near session lows as investors found little reason to be bullish. Housing data came in poor and failed to rally the bulls. Several Fed members raised the idea of a rate hike but “participants agreed that, with the unemployment rate approaching 6.5 percent, it would...

Despite being closed on Monday, U.S. markets had a relatively quiet day Tuesday. The Dow lost about 24 points to close at 16,130.40. The S&P was up 0.1 percent, or about two points, to 1,840.76 and the NASDAQ saw a sharp rise to finish 0.7 percent higher at 4,272.78. Wednesday morning, U....

U.S. stocks traded mostly higher today despite a key measure of home builder confidence falling in February. The New York Fed's general business index also showed signs of vulnerability. Despite the weak economic data which is partially due to weather, the Nasdaq index rose for the eight...

Here's a look at the top tickers trending on StockTwits.com. Forest Laboratories and Actavis: Major merger Investors woke up to news reports that Actavis (NYSE: ACT) has agreed to acquire Forest Laboratories (NYSE: FRX) for $25 billion in cash and stock. Investors will receive $26.04 in cash and...

Friday, the Dow ended the day 126.80 points higher to finish at 16,154.39. The S&P was up 0.5 percent, or about 9 points, to 1,838.63 and the NASDAQ was nearly flat to close at 4,244.02. This morning, U.S. markets are nearly flat. The Dow is indicated up about 6 points while the S&P is...

Major indices reversed Monday's losses and posted strong gains following a better than expected retail sales report and a luke-warm start to earnings season. Related: Stocks Higher, But Dollar Indecisive After Retail Sales Release Philidalphia's Fed chief Charles Plosser said that he wants QE...

Usually, a case has a winner and a loser—or at least somebody wins enough to be happy and the other loses enough to be upset. In this case, the winner was the U.S. government, but it didn’t win by much. The loser is Actavis (NYSE: ACT) and the rest of the pharma industry but it didn’t lose by...